JP2016533765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533765A5 JP2016533765A5 JP2016542824A JP2016542824A JP2016533765A5 JP 2016533765 A5 JP2016533765 A5 JP 2016533765A5 JP 2016542824 A JP2016542824 A JP 2016542824A JP 2016542824 A JP2016542824 A JP 2016542824A JP 2016533765 A5 JP2016533765 A5 JP 2016533765A5
- Authority
- JP
- Japan
- Prior art keywords
- wing segment
- linked nucleosides
- modified oligonucleotide
- segment
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 67
- 239000002777 nucleoside Substances 0.000 claims description 55
- 108091034117 Oligonucleotide Proteins 0.000 claims description 49
- 125000003835 nucleoside group Chemical group 0.000 claims description 45
- 230000000295 complement effect Effects 0.000 claims description 27
- 208000002780 macular degeneration Diseases 0.000 claims description 19
- 208000017169 kidney disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 230000037361 pathway Effects 0.000 claims description 12
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 11
- 208000016323 C3 glomerulonephritis Diseases 0.000 claims description 10
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 10
- 208000022401 dense deposit disease Diseases 0.000 claims description 10
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 10
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 7
- 230000008482 dysregulation Effects 0.000 claims description 7
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 7
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 claims description 5
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 claims description 5
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- -1 methoxyethyl Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 54
- 102000003712 Complement factor B Human genes 0.000 description 21
- 108090000056 Complement factor B Proteins 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877624P | 2013-09-13 | 2013-09-13 | |
| US61/877,624 | 2013-09-13 | ||
| PCT/US2014/055458 WO2015038939A2 (en) | 2013-09-13 | 2014-09-12 | Modulators of complement factor b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019201990A Division JP7158363B2 (ja) | 2013-09-13 | 2019-11-07 | 補体ｂ因子の調節薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533765A JP2016533765A (ja) | 2016-11-04 |
| JP2016533765A5 true JP2016533765A5 (OSRAM) | 2017-10-19 |
| JP6666250B2 JP6666250B2 (ja) | 2020-03-13 |
Family
ID=52666522
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542824A Active JP6666250B2 (ja) | 2013-09-13 | 2014-09-12 | 補体ｂ因子の調節薬 |
| JP2019201990A Active JP7158363B2 (ja) | 2013-09-13 | 2019-11-07 | 補体ｂ因子の調節薬 |
| JP2022011551A Active JP7297112B2 (ja) | 2013-09-13 | 2022-01-28 | 補体ｂ因子の調節薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019201990A Active JP7158363B2 (ja) | 2013-09-13 | 2019-11-07 | 補体ｂ因子の調節薬 |
| JP2022011551A Active JP7297112B2 (ja) | 2013-09-13 | 2022-01-28 | 補体ｂ因子の調節薬 |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US20160222389A1 (OSRAM) |
| EP (2) | EP3043827B1 (OSRAM) |
| JP (3) | JP6666250B2 (OSRAM) |
| KR (1) | KR102381790B1 (OSRAM) |
| CN (2) | CN112359042A (OSRAM) |
| AU (2) | AU2014318580B2 (OSRAM) |
| BR (1) | BR112016004671B1 (OSRAM) |
| CA (1) | CA2921842A1 (OSRAM) |
| CL (2) | CL2016000606A1 (OSRAM) |
| CR (1) | CR20160170A (OSRAM) |
| DK (1) | DK3043827T3 (OSRAM) |
| DO (1) | DOP2016000063A (OSRAM) |
| EA (1) | EA035433B1 (OSRAM) |
| ES (1) | ES2745758T3 (OSRAM) |
| HR (1) | HRP20191600T1 (OSRAM) |
| HU (1) | HUE045109T2 (OSRAM) |
| IL (1) | IL244095A0 (OSRAM) |
| LT (1) | LT3043827T (OSRAM) |
| MA (1) | MA38959A1 (OSRAM) |
| MX (2) | MX371518B (OSRAM) |
| MY (1) | MY181251A (OSRAM) |
| PE (2) | PE20190354A1 (OSRAM) |
| PH (1) | PH12016500443A1 (OSRAM) |
| PL (1) | PL3043827T3 (OSRAM) |
| PT (1) | PT3043827T (OSRAM) |
| RS (1) | RS59252B1 (OSRAM) |
| RU (1) | RU2662967C2 (OSRAM) |
| SG (2) | SG11201601445XA (OSRAM) |
| SI (1) | SI3043827T1 (OSRAM) |
| UA (1) | UA119046C2 (OSRAM) |
| WO (1) | WO2015038939A2 (OSRAM) |
| ZA (1) | ZA201601236B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2410053B2 (en) | 2006-10-18 | 2020-07-15 | Ionis Pharmaceuticals, Inc. | Antisense compounds |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| WO2012109395A1 (en) | 2011-02-08 | 2012-08-16 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| BR112015027322A8 (pt) | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | Compostos antissenso conjugados e sua utilização |
| BR112016004671B1 (pt) * | 2013-09-13 | 2020-12-29 | Ionis Pharmaceuticals, Inc. | compostos moduladores do fator b do complemento, composição compreendendo os referidos compostos e usos dos compostos ou da composição |
| AU2014362262B2 (en) * | 2013-12-12 | 2021-05-13 | Alnylam Pharmaceuticals, Inc. | Complement component iRNA compositions and methods of use thereof |
| MX380866B (es) * | 2014-05-01 | 2025-03-12 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del factor b del complemento. |
| TW201730341A (zh) * | 2016-02-05 | 2017-09-01 | Kyowa Hakko Kirin Co Ltd | 抑制補體b因子之表現之反義寡核苷酸 |
| SG11201811491YA (en) | 2016-06-27 | 2019-01-30 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| WO2018117253A1 (ja) * | 2016-12-23 | 2018-06-28 | 協和発酵キリン株式会社 | 補体ｂ因子の発現を抑制する核酸 |
| TW201909925A (zh) * | 2017-08-02 | 2019-03-16 | 日商協和醱酵麒麟有限公司 | 核酸複合體 |
| SG11202002940QA (en) | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| EP4048793A1 (en) | 2019-10-22 | 2022-08-31 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| CN116096381A (zh) * | 2020-04-30 | 2023-05-09 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
| CN114057692B (zh) | 2020-08-07 | 2023-07-21 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物、其制备方法及用途 |
| IL300432A (en) | 2020-08-07 | 2023-04-01 | Shanghai Meiyue Biotech Dev Co Ltd | An inhibitor of complement factor B, and the composition of the drugs, the method of preparation therefor and its use |
| AU2022325715A1 (en) | 2021-07-17 | 2024-02-01 | Sirnaomics, Inc. | Products and compositions |
| IL311146A (en) | 2021-09-02 | 2024-04-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell |
| CA3234636A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| WO2023129496A2 (en) * | 2021-12-27 | 2023-07-06 | Apellis Pharmaceuticals, Inc. | Rnas for complement inhibition |
| JP2025501178A (ja) | 2022-01-26 | 2025-01-17 | 上海美悦生物科技発展有限公司 | 補体因子ｂ阻害剤の塩形態、結晶形、並びにその製造方法及び使用 |
| CA3266935A1 (en) | 2022-09-10 | 2024-03-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses |
| JP2025537139A (ja) * | 2022-11-02 | 2025-11-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | 補体因子ｂの発現を調節するための方法 |
| AU2024261191A1 (en) | 2023-04-27 | 2025-11-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Salt of piperidylindole compound and preparation method therefor |
| WO2024245424A1 (zh) * | 2023-06-02 | 2024-12-05 | 维亚臻生物技术（苏州）有限公司 | 一种用于免疫类疾病的双链核苷酸化合物及其应用 |
| CN118620964A (zh) * | 2023-06-28 | 2024-09-10 | 百奥赛图(北京)医药科技股份有限公司 | 一种cfb基因修饰的非人动物 |
| TW202500169A (zh) * | 2023-06-28 | 2025-01-01 | 大陸商上海舶望製藥有限公司 | 用於抑制補體因子b(cfb)表達的組合物和方法 |
| WO2025122669A1 (en) * | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized complement factor b gene |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| DK0455905T3 (da) | 1990-05-11 | 1998-12-07 | Microprobe Corp | Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider |
| EP0538194B1 (de) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| ES2107205T3 (es) | 1993-03-30 | 1997-11-16 | Sanofi Sa | Analogos de nucleosidos aciclicos y secuencias oligonucleotidas que los contienen. |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| AU1705100A (en) * | 1998-10-09 | 2000-05-01 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
| KR20010112944A (ko) | 1999-04-21 | 2001-12-22 | 이곤 이 버그 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물 |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| AU2698301A (en) | 1999-12-30 | 2001-07-16 | K.U. Leuven Research And Development | Cyclohexene nucleic acids |
| US20040209276A1 (en) * | 2002-09-13 | 2004-10-21 | Smith Michael D. | Thermostable reverse transcriptases and uses thereof |
| EP1499627A2 (en) | 2001-07-03 | 2005-01-26 | ISIS Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| US6964950B2 (en) * | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP2957568B1 (en) | 2002-11-05 | 2016-12-21 | Ionis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| EP2213738B1 (en) | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| US20070123466A1 (en) * | 2003-05-13 | 2007-05-31 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of treating recurrent miscarriages |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| US7959919B2 (en) | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
| US7999082B2 (en) * | 2004-02-10 | 2011-08-16 | National Jewish Medical And Research Center | Anti-factor B antibodies |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| CA2569419A1 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| GB0521716D0 (en) * | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
| EP1984381B1 (en) | 2006-01-27 | 2010-09-29 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| ES2389737T3 (es) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en 5' |
| US8252755B2 (en) * | 2006-09-22 | 2012-08-28 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
| EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| JP5332064B2 (ja) * | 2007-03-01 | 2013-11-06 | ウェルスタット イムノセラピューティクス， エルエルシー | 炎症により特徴付けられる疾患の治療 |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
| PL2320925T3 (pl) * | 2008-07-10 | 2016-06-30 | Regenesance B V | Antagoniści dopełniacza i ich zastosowania |
| EP2361256B1 (en) | 2008-09-24 | 2013-04-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
| JP6005628B2 (ja) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物 |
| AU2011282217B2 (en) * | 2010-07-19 | 2015-12-03 | Ionis Pharmaceuticals, Inc. | Modulation of dystrophia myotonica-protein kinase (DMPK) expression |
| CA2832972C (en) * | 2011-04-13 | 2019-04-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
| BR112016004671B1 (pt) | 2013-09-13 | 2020-12-29 | Ionis Pharmaceuticals, Inc. | compostos moduladores do fator b do complemento, composição compreendendo os referidos compostos e usos dos compostos ou da composição |
| MX380866B (es) * | 2014-05-01 | 2025-03-12 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del factor b del complemento. |
-
2014
- 2014-09-12 BR BR112016004671-4A patent/BR112016004671B1/pt active IP Right Grant
- 2014-09-12 JP JP2016542824A patent/JP6666250B2/ja active Active
- 2014-09-12 SI SI201431272T patent/SI3043827T1/sl unknown
- 2014-09-12 LT LTEP14844168.6T patent/LT3043827T/lt unknown
- 2014-09-12 EP EP14844168.6A patent/EP3043827B1/en active Active
- 2014-09-12 PT PT14844168T patent/PT3043827T/pt unknown
- 2014-09-12 CN CN202011263979.3A patent/CN112359042A/zh active Pending
- 2014-09-12 EA EA201690582A patent/EA035433B1/ru unknown
- 2014-09-12 MA MA38959A patent/MA38959A1/fr unknown
- 2014-09-12 RS RSP20191160 patent/RS59252B1/sr unknown
- 2014-09-12 KR KR1020167009610A patent/KR102381790B1/ko active Active
- 2014-09-12 PE PE2018003111A patent/PE20190354A1/es unknown
- 2014-09-12 SG SG11201601445XA patent/SG11201601445XA/en unknown
- 2014-09-12 RU RU2016113763A patent/RU2662967C2/ru active
- 2014-09-12 WO PCT/US2014/055458 patent/WO2015038939A2/en not_active Ceased
- 2014-09-12 CN CN201480056788.6A patent/CN105744959B/zh active Active
- 2014-09-12 CA CA2921842A patent/CA2921842A1/en not_active Abandoned
- 2014-09-12 PL PL14844168T patent/PL3043827T3/pl unknown
- 2014-09-12 MY MYPI2016700852A patent/MY181251A/en unknown
- 2014-09-12 AU AU2014318580A patent/AU2014318580B2/en active Active
- 2014-09-12 ES ES14844168T patent/ES2745758T3/es active Active
- 2014-09-12 EP EP19182415.0A patent/EP3603677A1/en active Pending
- 2014-09-12 DK DK14844168.6T patent/DK3043827T3/da active
- 2014-09-12 HU HUE14844168A patent/HUE045109T2/hu unknown
- 2014-09-12 US US15/021,651 patent/US20160222389A1/en not_active Abandoned
- 2014-09-12 PE PE2016000376A patent/PE20160500A1/es unknown
- 2014-09-12 HR HRP20191600 patent/HRP20191600T1/hr unknown
- 2014-09-12 SG SG10201806787VA patent/SG10201806787VA/en unknown
- 2014-09-12 MX MX2016003263A patent/MX371518B/es active IP Right Grant
- 2014-12-09 UA UAA201603969A patent/UA119046C2/uk unknown
-
2016
- 2016-02-09 IL IL244095A patent/IL244095A0/en unknown
- 2016-02-22 ZA ZA2016/01236A patent/ZA201601236B/en unknown
- 2016-03-08 PH PH12016500443A patent/PH12016500443A1/en unknown
- 2016-03-11 MX MX2020001258A patent/MX2020001258A/es unknown
- 2016-03-11 DO DO2016000063A patent/DOP2016000063A/es unknown
- 2016-03-14 CL CL2016000606A patent/CL2016000606A1/es unknown
- 2016-04-12 CR CR20160170A patent/CR20160170A/es unknown
-
2018
- 2018-03-05 US US15/912,386 patent/US20190048351A1/en not_active Abandoned
- 2018-08-14 CL CL2018002334A patent/CL2018002334A1/es unknown
-
2019
- 2019-06-12 US US16/439,317 patent/US20200149047A1/en not_active Abandoned
- 2019-11-07 JP JP2019201990A patent/JP7158363B2/ja active Active
-
2020
- 2020-03-11 AU AU2020201763A patent/AU2020201763A1/en not_active Abandoned
-
2021
- 2021-09-02 US US17/465,035 patent/US11926830B2/en active Active
-
2022
- 2022-01-28 JP JP2022011551A patent/JP7297112B2/ja active Active
-
2024
- 2024-02-02 US US18/431,253 patent/US20240247268A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533765A5 (OSRAM) | ||
| JP7297112B2 (ja) | 補体ｂ因子の調節薬 | |
| US12110491B2 (en) | Selective reduction of allelic variants | |
| CA2918600C (en) | Compositions for modulating tau expression | |
| JP7007304B2 (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP6606557B2 (ja) | Ｃ９ｏｒｆ７２発現を調節するための組成物 | |
| US9752142B2 (en) | Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof | |
| CN110724687B (zh) | 用于调节补体因子b表达的组合物和方法 | |
| EP3208347B1 (en) | Selective reduction of allelic variants | |
| JP2013226147A5 (OSRAM) | ||
| JP2016530882A5 (OSRAM) | ||
| CN102482672B (zh) | 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 | |
| JP2016116520A5 (OSRAM) | ||
| JP2016530882A (ja) | 筋強直性ジストロフィープロテインキナーゼ（ｄｍｐｋ）の発現を調節するための化合物及び方法 | |
| BR112016020472B1 (pt) | Oligonucleotídeo modificado de fita simples, e composição farmacêutica | |
| JP2016513976A5 (OSRAM) | ||
| TW202039842A (zh) | 治療黃斑退化之組合治療 | |
| AU2022203490A1 (en) | Organic compositions to treat epas1-related diseases | |
| KR20150004414A (ko) | Kras-관련 질환을 치료하기 위한 유기 조성물 | |
| EP2683411A1 (en) | Methods of using microrna-26a to promote angiogenesis | |
| KR102508432B1 (ko) | eIF4E 저해제를 포함하는 eIF4E 활성증가와 관련된 상태의 진단 또는 치료용 조성물 | |
| RU2018127385A (ru) | Модуляторы фактора в комплемента |